Autres langues BioHarvest Sciences Inc. Canadian Securities Exchange

Actions

BHSC

CA13767B1013

Produits pharmaceutiques

Temps Différé Canadian Securities Exchange Autres places de cotation 16:24:58 05/10/2021			Varia. 5j.	Varia. 1 janv.
0,3500 ^CAD	+6,06%		-2,94%	+46,67%

18/05	Tate & Lyle et BioHarvest Sciences renforcent leur collaboration pour le développement de molécules édulcorantes végétales de nouvelle génération	CI
14/05	BioHarvest Sciences Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Autres langues

15/07	BioHarvest Sciences Inc. Receives $1.4 Million Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell Synthesis
15/07	BioHarvest Awarded $1.4M Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell Synthesis
14/07	BioHarvest Sciences to Participate in the 'Health, Wellness & Longevity' Virtual Conference Presented by Maxim Group LLC
13/07	BioHarvest Sciences : to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC
13/07	BioHarvest Sciences to Participate in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC
18/06	BioHarvest Sciences to Present at the 2026 BIO International Convention
18/05	Tate & Lyle And BioHarvest Sciences Expand Collaboration For Next-Generation Plant-Based Sweetener Molecule Development
18/05	Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation
14/05	BioHarvest Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
14/05	BioHarvest Sciences : First Quarter 2026 Financial Statements
14/05	BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
13/05	BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division
13/05	BioHarvest Sciences Inc. Announces Successful Completion Of Stage 1 Development Of Saffron Composition For Nutraceutical And Culinary Applications
13/05	BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications
12/05	BioHarvest Sciences Signs $1.2 Million CDMO Stage2 Contract for the Development of A Rare Fragrance Using Its Proprietary Botanical Synthesis Platform
12/05	BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform
01/05	BioHarvest Sciences : BHST May 2026 Investor Presentation
30/04	BioHarvest Sciences to Report First Quarter 2026 Financial Results on May 14, 2026
29/04	BioHarvest Sciences Inc. Announces CEO Changes
29/04	BioHarvest Sciences Inc. Appoints Ilan Sobel to the Company's Board of Directors
29/04	BioHarvest Sciences Announces Strategic Leadership Transition with Dr. Zaki Rakib Assuming Role of Chief Executive Officer to Accelerate "Two-Lens" Growth Strategy
31/03	BioHarvest Sciences Provides Earnings Guidance for Fiscal Year 2026
31/03	BioHarvest Sciences Reports Fourth Quarter and Full-Year 2025 Financial Results
31/03	BioHarvest Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
31/03	Bioharvest Sciences Announces Successful Stable Cell Culture Development for Rare Fragrance-Producing Plant